An Open-Label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL Tablets (Risperidone) to an Equivalent Dose of a Rapidly-Dissolving Tablet Formulation of Risperidone.

Trial Profile

An Open-Label Study Evaluating the Maintenance of Clinical Effect in Adults With Schizophrenia Switched From RISPERDAL Tablets (Risperidone) to an Equivalent Dose of a Rapidly-Dissolving Tablet Formulation of Risperidone.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2010

At a glance

  • Drugs Risperidone (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Janssen Inc
  • Most Recent Events

    • 14 Apr 2009 Planned number of patients changed from 100 to 82 as reported by ClinicalTrials.gov.
    • 19 Oct 2007 Status changed from in progress to completed.
    • 08 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top